Fate Therapeutics Inc (NAS:FATE) Stock News, Headlines & Updates
Fate Therapeutics Inc Stock News from GuruFocus
- 1
Jun 12, 2025
FATE: Analyst Maintains Hold Rating on Fate Therapeutics | FATE Stock News
GuruFocus News • 8:00am
Jun 11, 2025
Fate Therapeutics (FATE) Shares Promising Data on FT819 for Lupus Treatment | FATE Stock News
GuruFocus News • 8:31am
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
GuruFocus News • 8:23am
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
Marketwired • 8:00am
May 30, 2025
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
Marketwired • 4:00pm
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors | FATE Stock News
GuruFocus News • 3:45pm
May 28, 2025
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress | FATE Stock News
GuruFocus News • 5:15pm
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
GlobeNewswire • 5:00pm
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
Marketwired • 5:00pm
May 14, 2025
Fate Therapeutics (FATE) Faces Significant Price Target Reduction | FATE Stock News
GuruFocus News • 10:37am
FATE Stock Update: Analyst Lowers Price Target, Maintains Neutral Rating | FATE Stock News
GuruFocus News • 8:39am
FATE: Analyst Reiterates Hold Rating for Fate Therapeutics | FATE Stock News
GuruFocus News • 7:02am
Baird Revises Fate Therapeutics (FATE) Price Target Post-Q1 Results | FATE Stock News
GuruFocus News • 6:31am
Barclays Adjusts Fate Therapeutics (FATE) Price Target Amid Q1 Results | FATE Stock News
GuruFocus News • 5:17am
Fate Therapeutics Inc (FATE) Q1 2025 Earnings: EPS of -$0.32 Beats Estimate, Revenue Surpasses Expectations at $1.6 Million
GuruFocus News • 7:05pm
May 13, 2025
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
Marketwired • 4:00pm
FATE Therapeutics Exceeds Revenue Estimates with Strong CAR T-Cell Program | FATE Stock News
GuruFocus News • 3:37pm
May 02, 2025
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Marketwired • 4:00pm
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | FATE Stock News
GuruFocus News • 3:18pm
Apr 29, 2025
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
Marketwired • 9:00am
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting | FATE Stock News
GuruFocus News • 8:45am
Apr 14, 2025
Fate Therapeutics (FATE) Gains FDA RMAT Designation for Lupus Treatment
GuruFocus News • 10:58am
Fate Therapeutics (FATE) Receives FDA RMAT Designation for Innovative Lupus Therapy | FATE Stock News
GuruFocus News • 7:32am
- 1
Show
Entries
Headlines
Total 0- 1
No recent news